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:   end‐binding protein 3
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:   IP~3~‐binding core
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IP~3~R

:   IP~3~ receptor

IRBIT

:   IP~3~R‐binding protein released with IP~3~
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PKA

:   protein kinase A
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:   phospholipase C
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:   suppressor domain
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:   transmembrane domain

Introduction {#tjp7102-sec-0020}
============

Ca^2+^ signals within cells are spatially and temporally intricate, allowing them to elicit a multitude of specific downstream effects (Berridge, [2009](#tjp7102-bib-0011){ref-type="ref"}). Inositol 1,4,5‐trisphosphate receptors (IP~3~Rs), the most widely expressed class of intracellular Ca^2+^ channel, release Ca^2+^ from intracellular stores in response to binding of IP~3~ and Ca^2+^ (Foskett *et al*. [2007](#tjp7102-bib-0038){ref-type="ref"}; Taylor & Tovey, [2010](#tjp7102-bib-0151){ref-type="ref"}). Dual regulation of IP~3~Rs by two essential stimuli, IP~3~ and Ca^2+^, is important because it endows IP~3~Rs with a capacity to propagate Ca^2+^ signals regeneratively by Ca^2+^‐induced Ca^2+^ release, as Ca^2+^ released by an active IP~3~R ignites the activity of adjacent IP~3~Rs that have bound IP~3~ (Smith & Parker, [2009](#tjp7102-bib-0136){ref-type="ref"}). This in turn plays a key role in defining the spatial organization of IP~3~‐evoked Ca^2+^ signals.

Activation of IP~3~Rs is initiated by binding of IP~3~ within a clam‐like structure, the IP~3~‐binding core (IBC) (Bosanac *et al*. [2002](#tjp7102-bib-0016){ref-type="ref"}), located near the N‐terminus of each IP~3~R subunit. Binding of IP~3~ causes a conformational change that rearranges the association of the IBC with the N‐terminal suppressor domain (SD). These changes are proposed to disrupt interactions between the N‐terminal regions of the four subunits of the IP~3~R, leading to opening of the channel. The latter is formed by transmembrane domains (TMDs) towards the C‐terminus of each IP~3~R subunit (Seo *et al*. [2012](#tjp7102-bib-0131){ref-type="ref"}) (Fig. [1](#tjp7102-fig-0001){ref-type="fig"}). It is not yet clear where binding of Ca^2+^ to the IP~3~R lies within the sequence of events linking binding of IP~3~ to channel gating. One possibility is that the conformational changes evoked by binding of IP~3~ expose a site to which Ca^2+^ must bind before the channel can open (Marchant & Taylor, [1997](#tjp7102-bib-0087){ref-type="ref"}; Foskett *et al*. [2007](#tjp7102-bib-0038){ref-type="ref"}). However, neither the structural identity of this stimulatory Ca^2+^‐binding site, nor that of the inhibitory site through which higher concentrations of Ca^2+^ inhibit IP~3~Rs have been resolved. The inhibitory site may reside on an accessory protein associated with IP~3~Rs.

![**Association of proteins with IP~3~Rs**\
Key functional domains of a single IP~3~R subunit are shown: the suppressor domain (SD), IP~3~‐binding core (IBC), cytosolic regulatory domain, transmembrane domains (TMDs) and the cytosolic C‐terminus (CT). The sites to which proteins are proposed to bind are shown. Many additional proteins are thought to associate with IP~3~Rs, but the binding sites have not been identified. Abbreviations and references are provided in Tables [1](#tjp7102-tbl-0001){ref-type="table-wrap"}, [2](#tjp7102-tbl-0002){ref-type="table-wrap"}, [3](#tjp7102-tbl-0003){ref-type="table-wrap"}, [4](#tjp7102-tbl-0004){ref-type="table-wrap"}.](TJP-594-2849-g002){#tjp7102-fig-0001}

IP~3~Rs are present in almost all animal cells and some protozoa (Prole & Taylor, [2011](#tjp7102-bib-0118){ref-type="ref"}), but there are no homologous proteins in plants (Wheeler & Brownlee, [2008](#tjp7102-bib-0173){ref-type="ref"}) or fungi (Prole & Taylor, [2012](#tjp7102-bib-0119){ref-type="ref"}). The genomes of vertebrates encode three subtypes of IP~3~R subunit (IP~3~R1--3), which can form homo‐tetrameric or hetero‐tetrameric channels (Joseph *et al*. [1995](#tjp7102-bib-0065){ref-type="ref"}) with differing properties and distributions (Foskett *et al*. [2007](#tjp7102-bib-0038){ref-type="ref"}; Mikoshiba, [2007](#tjp7102-bib-0094){ref-type="ref"}). In mammalian cells, IP~3~Rs have been reported to release Ca^2+^ mainly from the endoplasmic reticulum (ER) (Streb *et al*. [1984](#tjp7102-bib-0139){ref-type="ref"}; Volpe *et al*. [1985](#tjp7102-bib-0166){ref-type="ref"}), but the Golgi apparatus (Pinton *et al*. [1998](#tjp7102-bib-0117){ref-type="ref"}) and secretory vesicles (Yoo, [2011](#tjp7102-bib-0181){ref-type="ref"}) also respond to IP~3~. Although IP~3~ initiates Ca^2+^ signals by stimulating Ca^2+^ release from intracellular stores, the signals are sustained by Ca^2+^ entry across the plasma membrane. That too is indirectly regulated by IP~3~, because store‐operated Ca^2+^ entry is stimulated by loss of Ca^2+^ from the ER (Parekh & Putney, [2005](#tjp7102-bib-0112){ref-type="ref"}; Lewis, [2012](#tjp7102-bib-0078){ref-type="ref"}). Ca^2+^ signals initiated by IP~3~Rs evoke a wide variety of cellular events, ranging from embryological development (Kume *et al*. [1997](#tjp7102-bib-0075){ref-type="ref"}; Uchida *et al*. [2010](#tjp7102-bib-0161){ref-type="ref"}) to cellular metabolism (Cardenas *et al*. [2010](#tjp7102-bib-0022){ref-type="ref"}), gluconeogenesis (Wang *et al*. [2012](#tjp7102-bib-0170){ref-type="ref"}), exocrine secretion (Futatsugi *et al*. [2005](#tjp7102-bib-0042){ref-type="ref"}) and neuronal function (Matsumoto *et al*. [1996](#tjp7102-bib-0088){ref-type="ref"}).

Specificity within Ca^2+^ signalling pathways, or indeed any signalling pathway (Scott & Pawson, [2009](#tjp7102-bib-0130){ref-type="ref"}; Scott *et al*. [2013](#tjp7102-bib-0129){ref-type="ref"}), is achieved, in part, by the formation of macromolecular signalling complexes. Within the signalling pathways that involve phospholipase C (PLC), these complexes regulate the activity of IP~3~Rs, their distribution, and their association with both the plasma membrane receptors that evoke IP~3~ formation and the downstream targets of the Ca^2+^ released by IP~3~Rs (Konieczny *et al*. [2012](#tjp7102-bib-0073){ref-type="ref"}). The interactions of IP~3~Rs with other proteins have been reviewed previously (Choe & Ehrlich, [2006](#tjp7102-bib-0029){ref-type="ref"}; Foskett *et al*. [2007](#tjp7102-bib-0038){ref-type="ref"}; Mikoshiba, [2007](#tjp7102-bib-0094){ref-type="ref"}; Vanderheyden *et al*. [2009](#tjp7102-bib-0162){ref-type="ref"} *a*), but continued progress and the advent of high‐throughput proteomics methods (Havugimana *et al*. [2012](#tjp7102-bib-0049){ref-type="ref"}; Rolland *et al*. [2014](#tjp7102-bib-0123){ref-type="ref"}) suggest that an update is timely.

Searches of proteomic databases and published literature reveal a large number of proteins that form complexes with IP~3~Rs (Tables [1](#tjp7102-tbl-0001){ref-type="table-wrap"}, [2](#tjp7102-tbl-0002){ref-type="table-wrap"}, [3](#tjp7102-tbl-0003){ref-type="table-wrap"}, [4](#tjp7102-tbl-0004){ref-type="table-wrap"}). For some of these proteins, the regions within IP~3~Rs that are important for the interaction have been mapped (Fig. [1](#tjp7102-fig-0001){ref-type="fig"}). At the outset, it is worth sounding some notes of caution regarding the reported interactions. Firstly, it is often difficult to establish that two proteins interact directly, rather than via intermediate proteins. Many of these complexes may, therefore, be formed by direct or indirect interactions of IP~3~Rs with other proteins. For example, association of protein phosphatase 1 with IP~3~Rs may be mediated in part by IRBIT (IP~3~R‐binding protein released with IP~3~), which binds directly to both proteins (Ando *et al*. [2014](#tjp7102-bib-0002){ref-type="ref"}). Secondly, the interactions and their effects may depend on the cellular context, including such factors as the subtype of IP~3~R, the physiological status of the IP~3~R (e.g. phosphorylation), the cell type and the expression levels of the interacting proteins and IP~3~Rs. Thirdly, interactions that occur in cellular lysates may be precluded within intact cells. For example, the interaction of two proteins may be prevented by their physical separation within the cell or by mutually exclusive binding of other proteins or ligands. IRBIT, for example, binds to IP~3~R subunits only when they have no IP~3~ bound. Lastly, some forms of experimental evidence are more discriminating than others, and it will be necessary to verify the putative interactions indicated by methods such as yeast two‐hybrid screening and mass spectrometry.

###### 

Proteins that form complexes with IP~3~Rs and enhance their activity

  Protein                                                                                             References
  --------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Effective delivery of messengers                                                                    
  Adenylyl cyclase 6 (AC6)                                                                            Tovey *et al*. [2008](#tjp7102-bib-0156){ref-type="ref"}
  Bradykinin receptor B~2~ (B~2~R)                                                                    Delmas *et al*. [2002](#tjp7102-bib-0032){ref-type="ref"}; Jin *et al*. [2013](#tjp7102-bib-0063){ref-type="ref"}
  Epidermal growth factor receptor (EGFR)                                                             Hur *et al*. [2005](#tjp7102-bib-0059){ref-type="ref"}
  Erythropoietin receptor (EPO‐R)                                                                     Tong *et al*. [2004](#tjp7102-bib-0155){ref-type="ref"}
  Glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH)                                                    Patterson *et al*. [2005](#tjp7102-bib-0114){ref-type="ref"}
  Metabotropic glutamate receptor 1 (mGluR1;GRM1)                                                     Tu *et al*. [1998](#tjp7102-bib-0160){ref-type="ref"}
  Phospholipase C‐β1 (PLCβ1)                                                                          Shin *et al*. [2000](#tjp7102-bib-0132){ref-type="ref"}
  Phospholipase C‐β4 (PLCβ4)                                                                          Nakamura *et al*. [2004](#tjp7102-bib-0103){ref-type="ref"}
  Phospholipase C‐γ1 (PLCγ1)                                                                          Tong *et al*. [2004](#tjp7102-bib-0155){ref-type="ref"}; Yuan *et al*. [2005](#tjp7102-bib-0185){ref-type="ref"}
  Protease‐activated receptor 2 (PAR‐2)                                                               Jin *et al*. [2013](#tjp7102-bib-0063){ref-type="ref"}
  Sensitization to IP~3~/Ca^2^ ***^+^***                                                              
  Bcl‐2 (B‐cell lymphoma 2)[a](#tjp7102-tbl1-note-0001){ref-type="fn"}                                Chen *et al*. [2004](#tjp7102-bib-0026){ref-type="ref"}; Eckenrode *et al*. [2010](#tjp7102-bib-0036){ref-type="ref"}; Monaco *et al*. [2012](#tjp7102-bib-0097){ref-type="ref"}; Chang *et al*. [2014](#tjp7102-bib-0023){ref-type="ref"}
  Bcl‐X~L~ (B‐cell lymphoma extra large)                                                              White *et al*. [2005](#tjp7102-bib-0174){ref-type="ref"}; Eckenrode *et al*. [2010](#tjp7102-bib-0036){ref-type="ref"}; Monaco *et al*. [2012](#tjp7102-bib-0097){ref-type="ref"}
  Chromogranin A (CGA)                                                                                Yoo & Lewis, [1998](#tjp7102-bib-0182){ref-type="ref"}; Thrower *et al*. [2002](#tjp7102-bib-0153){ref-type="ref"}
  Chromogranin B (CGB; secretogranin‐1)                                                               Yoo & Lewis, [2000](#tjp7102-bib-0183){ref-type="ref"}; Thrower *et al*. [2003](#tjp7102-bib-0152){ref-type="ref"}
  Cyclin‐A                                                                                            Soghoian *et al*. [2005](#tjp7102-bib-0138){ref-type="ref"}
  Cyclin‐B1 (CYB)                                                                                     Malathi *et al*. [2003](#tjp7102-bib-0085){ref-type="ref"}; Malathi *et al*. [2005](#tjp7102-bib-0086){ref-type="ref"}
  Cyclin‐dependent kinase 1 (CDK1)                                                                    Malathi *et al*. [2003](#tjp7102-bib-0085){ref-type="ref"}; Malathi *et al*. [2005](#tjp7102-bib-0086){ref-type="ref"}
  Cytochrome *c* ~1~                                                                                  Boehning *et al*. [2004](#tjp7102-bib-0013){ref-type="ref"}
  Fyn (tyrosine‐protein kinase)                                                                       Jayaraman *et al*. [1996](#tjp7102-bib-0062){ref-type="ref"}; Cui *et al*. [2004](#tjp7102-bib-0031){ref-type="ref"}
  Glucosidase 2 subunit β (80K‐H)                                                                     Kawaai *et al*. [2009](#tjp7102-bib-0067){ref-type="ref"}
  Glycogen synthase kinase‐3β (GSK3β)                                                                 Gomez *et al*. [2016](#tjp7102-bib-0045){ref-type="ref"}
  Huntingtin‐associated protein 1 (HAP‐1)                                                             Tang *et al*. [2003](#tjp7102-bib-0148){ref-type="ref"} *b*
  Huntingtin (HTT) (with poly‐Q expansion, HTT^exp^)[b](#tjp7102-tbl1-note-0001){ref-type="fn"}       Tang *et al*. [2003](#tjp7102-bib-0148){ref-type="ref"} *b*
  Lyn (tyrosine‐protein kinase)                                                                       Yokoyama *et al*. [2002](#tjp7102-bib-0180){ref-type="ref"}
  Mcl‐1 (myeloid cell leukemia‐1)                                                                     Eckenrode *et al*. [2010](#tjp7102-bib-0036){ref-type="ref"}
  mTOR (mammalian target of rapamycin)                                                                Fregeau *et al*. [2011](#tjp7102-bib-0040){ref-type="ref"}
  Neuronal Ca^2+^ sensor 1 (NCS‐1)                                                                    Schlecker *et al*. [2006](#tjp7102-bib-0126){ref-type="ref"}
  Polo‐like kinase 1 (PLK1)                                                                           Ito *et al*. [2008](#tjp7102-bib-0061){ref-type="ref"}; Vanderheyden *et al*. [2009](#tjp7102-bib-0163){ref-type="ref"} *b*
  Presenilin‐1/Presenilin‐2 (PS‐1/PS‐2)                                                               Cheung *et al*. [2008](#tjp7102-bib-0028){ref-type="ref"}
  Protein kinase A (PKA; cAMP‐dependent protein kinase)                                               Ferris *et al*. [1991](#tjp7102-bib-0037){ref-type="ref"}; Bruce *et al*. [2002](#tjp7102-bib-0019){ref-type="ref"}
  Receptor of activated protein kinase C1 (RACK1)                                                     Patterson *et al*. [2004](#tjp7102-bib-0113){ref-type="ref"}
  Rho‐associated protein kinase (ROCK)                                                                Singleton & Bourguignon, [2002](#tjp7102-bib-0134){ref-type="ref"}
  TRISK 32 (cardiac triadin TRISK 32 isoform)                                                         Olah *et al*. [2011](#tjp7102-bib-0108){ref-type="ref"}
  Direct activation of IP~3~Rs                                                                        
  Ca^2+^‐binding protein 1 (CaBP1)[c](#tjp7102-tbl1-note-0001){ref-type="fn"}                         Yang *et al*. [2002](#tjp7102-bib-0179){ref-type="ref"}; Li *et al*. [2013](#tjp7102-bib-0079){ref-type="ref"}
  CIB1 (Ca^2+^ and integrin‐binding protein 1; calmyrin)[c](#tjp7102-tbl1-note-0001){ref-type="fn"}   White *et al*. [2006](#tjp7102-bib-0175){ref-type="ref"}
  Gβγ complex                                                                                         Shin *et al*. [2000](#tjp7102-bib-0132){ref-type="ref"}; Zeng *et al*. [2003](#tjp7102-bib-0187){ref-type="ref"}
  Other                                                                                               
  DARPP‐32 (protein phosphatase 1 regulatory subunit 1B)                                              Chang *et al*. [2014](#tjp7102-bib-0023){ref-type="ref"}
  DHHC6                                                                                               Fredericks *et al*. [2014](#tjp7102-bib-0039){ref-type="ref"}
  EB3 (end‐binding protein 3)                                                                         Geyer *et al*. [2015](#tjp7102-bib-0044){ref-type="ref"}
  GRP‐78 (78 kDa glucose‐regulated protein; BiP)                                                      Higo *et al*. [2010](#tjp7102-bib-0052){ref-type="ref"}
  Phosphatidylinositol trisphosphate 3‐phosphatase (PTEN)                                             Bononi *et al*. [2013](#tjp7102-bib-0015){ref-type="ref"}
  Selenoprotein K (SELK)                                                                              Fredericks *et al*. [2014](#tjp7102-bib-0039){ref-type="ref"}

Data for Tables [1](#tjp7102-tbl-0001){ref-type="table-wrap"}, [2](#tjp7102-tbl-0002){ref-type="table-wrap"}, [3](#tjp7102-tbl-0003){ref-type="table-wrap"}, [4](#tjp7102-tbl-0004){ref-type="table-wrap"} were derived from manual searches of the literature, reviews (Choe & Ehrlich, [2006](#tjp7102-bib-0029){ref-type="ref"}; Foskett *et al*. [2007](#tjp7102-bib-0038){ref-type="ref"}; Mikoshiba, [2007](#tjp7102-bib-0094){ref-type="ref"}; Vanderheyden *et al*. [2009](#tjp7102-bib-0162){ref-type="ref"} *a*) and databases, including BioGRID (Chatr‐Aryamontri *et al*. [2015](#tjp7102-bib-0024){ref-type="ref"}) and IntAct (Orchard *et al*. [2013](#tjp7102-bib-0109){ref-type="ref"}). The nomenclature of proteins shown is consistent with the human homologues, although some data are derived from interactions of IP~3~Rs and proteins from other species. ^a^Some studies report sensitization of IP~3~Rs by Bcl‐2, while others report inhibition. ^b^HTT^exp^, but not wild‐type HTT, sensitizes IP~3~Rs to IP~3~/Ca^2+^. ^c^CaBP1 and CIB1 are also reported to inhibit IP~3~Rs (see Table [2](#tjp7102-tbl-0002){ref-type="table-wrap"}); direct activation seems to occur only transiently, and is controversial.
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###### 

Proteins that form complexes with IP~3~Rs and inhibit their activity

  Protein                                                                                             References
  --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Proteins that bind reversibly and disrupt activation by IP~3~ and/or Ca^2+^                         
  Ankyrin‐R (ANK1)                                                                                    Bourguignon *et al*. [1993](#tjp7102-bib-0018){ref-type="ref"}; Joseph & Samanta, [1993](#tjp7102-bib-0066){ref-type="ref"}
  Bcl‐2 (B‐cell lymphoma 2)[a](#tjp7102-tbl2-note-0001){ref-type="fn"}                                Chen *et al*. [2004](#tjp7102-bib-0026){ref-type="ref"}; Monaco *et al*. [2012](#tjp7102-bib-0097){ref-type="ref"}; Chang *et al*. [2014](#tjp7102-bib-0023){ref-type="ref"}
  Ca^2+^‐binding protein 1 (CaBP1)[b](#tjp7102-tbl2-note-0001){ref-type="fn"}                         Yang *et al*. [2002](#tjp7102-bib-0179){ref-type="ref"}; Li *et al*. [2013](#tjp7102-bib-0079){ref-type="ref"}
  Calmodulin (CaM)                                                                                    Maeda *et al*. [1991](#tjp7102-bib-0083){ref-type="ref"}; Yamada *et al*. [1995](#tjp7102-bib-0178){ref-type="ref"}
  Carbonic anhydrase‐related protein (CARP; CA8)                                                      Hirota *et al*. [2003](#tjp7102-bib-0054){ref-type="ref"}
  Caspase‐3                                                                                           Hirota *et al*. [1999](#tjp7102-bib-0055){ref-type="ref"}
  CIB1 (Ca^2+^ and integrin‐binding protein 1; calmyrin)[b](#tjp7102-tbl2-note-0001){ref-type="fn"}   White *et al*. [2006](#tjp7102-bib-0175){ref-type="ref"}
  DANGER (IP~3~R‐interacting protein)                                                                 van Rossum *et al*. [2006](#tjp7102-bib-0164){ref-type="ref"}
  ERp44 (endoplasmic reticulum resident protein 44)                                                   Higo *et al*. [2005](#tjp7102-bib-0053){ref-type="ref"}
  FKBP1A (FK506‐binding protein 1A; FKBP12)                                                           Cameron *et al*. [1995](#tjp7102-bib-0021){ref-type="ref"} *b*
  GIT1/GIT2 (ARF GTPase‐activating protein 1/2)                                                       Zhang *et al*. [2009](#tjp7102-bib-0188){ref-type="ref"}
  IRBIT (IP~3~‐binding protein released with IP~3~)                                                   Ando *et al*. [2003](#tjp7102-bib-0003){ref-type="ref"}
  K‐Ras                                                                                               Sung *et al*. [2013](#tjp7102-bib-0142){ref-type="ref"}
  MRVI1 (IRAG; IP~3~R‐associated cGMP kinase substrate)                                               Schlossman *et al*. [2000](#tjp7102-bib-0127){ref-type="ref"}
  Nuclear protein localization protein 4 homologue (NPL4)                                             Alzayady *et al*. [2005](#tjp7102-bib-0001){ref-type="ref"}
  Polycystin‐1 (PC1; TRPP1)                                                                           Li *et al*. [2005](#tjp7102-bib-0080){ref-type="ref"}
  Proteins that post‐translationally modify IP~3~Rs                                                   
  AKT1 (RAC‐α serine/threonine protein kinase; PKB)                                                   Khan *et al*. [2006](#tjp7102-bib-0069){ref-type="ref"}; Szado *et al*. [2008](#tjp7102-bib-0144){ref-type="ref"}
  Ca^2+^/calmodulin‐dependent protein kinase II (CaMKII)                                              Ferris *et al*. [1991](#tjp7102-bib-0037){ref-type="ref"}; Bare *et al*. [2005](#tjp7102-bib-0008){ref-type="ref"}
  Calpain                                                                                             Μagnusson *et al*. [1993](#tjp7102-bib-0084){ref-type="ref"}; Wojcikiewicz & Oberdorf, [1996](#tjp7102-bib-0176){ref-type="ref"}
  E3 ubiquitin ligase AMFR (GP78)[c](#tjp7102-tbl2-note-0001){ref-type="fn"}                          Pearce *et al*. [2007](#tjp7102-bib-0115){ref-type="ref"}
  E3 ubiquitin ligase RNF170[c](#tjp7102-tbl2-note-0001){ref-type="fn"}                               Lu *et al*. [2011](#tjp7102-bib-0081){ref-type="ref"}
  Erlin‐1/Erlin‐2 (SPFH domain‐containing protein 1/2)[c](#tjp7102-tbl2-note-0001){ref-type="fn"}     Pearce *et al*. [2007](#tjp7102-bib-0115){ref-type="ref"}; Pearce *et al*. [2009](#tjp7102-bib-0116){ref-type="ref"}
  MAPK1/MAPK3 (mitogen‐activated protein kinase 1/3)                                                  Bai *et al*. [2006](#tjp7102-bib-0007){ref-type="ref"}
  Protein phosphatase 1A (PP1A)                                                                       Tang *et al*. [2003](#tjp7102-bib-0149){ref-type="ref"} *a*; Chang *et al*. [2014](#tjp7102-bib-0023){ref-type="ref"}
  Transglutaminase‐2 (TGM2)                                                                           Hamada *et al*. [2014](#tjp7102-bib-0047){ref-type="ref"}
  Transitional endoplasmic reticulum ATPase (p97)[c](#tjp7102-tbl2-note-0001){ref-type="fn"}          Alzayady *et al*. [2005](#tjp7102-bib-0001){ref-type="ref"}
  Ubiquitin[c](#tjp7102-tbl2-note-0001){ref-type="fn"}                                                Bokkala & Joseph, [1997](#tjp7102-bib-0014){ref-type="ref"}; Oberdorf *et al*. [1999](#tjp7102-bib-0107){ref-type="ref"}
  Ubiquitin‐conjugating enzyme E2 7 (UBC7)[c](#tjp7102-tbl2-note-0001){ref-type="fn"}                 Webster *et al*. [2003](#tjp7102-bib-0171){ref-type="ref"}
  Ubiquitin conjugation factor E4A (UFD2)[c](#tjp7102-tbl2-note-0001){ref-type="fn"}                  Alzayady *et al*. [2005](#tjp7102-bib-0001){ref-type="ref"}
  Ubiquitin fusion degradation 1 protein (UFD1)[c](#tjp7102-tbl2-note-0001){ref-type="fn"}            Alzayady *et al*. [2005](#tjp7102-bib-0001){ref-type="ref"}

Bcl‐2 has also been reported to sensitize IP~3~Rs to IP~3~/Ca^2+^ (see Table [1](#tjp7102-tbl-0001){ref-type="table-wrap"}). ^b^CaBP1 and CIB1 may also cause transient activation of IP~3~Rs, although this is controversial (see Table [1](#tjp7102-tbl-0001){ref-type="table-wrap"}). ^c^Components of the proteasomal pathway.
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###### 

Proteins that form complexes with IP~3~Rs and act as downstream effectors

  Protein                                                                                        References
  ---------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Anoctamin‐1 (ANO1, Ca^2+^‐activated Cl^−^ channel)                                             Jin *et al*. [2013](#tjp7102-bib-0063){ref-type="ref"}
  Calcineurin (CN; protein phosphatase 2B)                                                       Cameron *et al*. [1995](#tjp7102-bib-0020){ref-type="ref"} *a*; Chang *et al*. [2014](#tjp7102-bib-0023){ref-type="ref"}
  CASK (Ca^2+^/calmodulin‐dependent serine protein kinase)                                       Maximov *et al*. [2003](#tjp7102-bib-0091){ref-type="ref"}
  CRTC2 (CREB‐regulated transcription coactivator 2)                                             Wang *et al*. [2012](#tjp7102-bib-0170){ref-type="ref"}
  IRBIT (IP~3~‐binding protein released with IP~3~)[a](#tjp7102-tbl3-note-0001){ref-type="fn"}   Ando *et al*. [2003](#tjp7102-bib-0003){ref-type="ref"}
  KCa1.1 (BK~Ca~; large conductance Ca^2+^‐activated K^+^ channel)                               Zhao *et al*. [2010](#tjp7102-bib-0190){ref-type="ref"}; Mound *et al*. [2013](#tjp7102-bib-0098){ref-type="ref"}
  Na^+^/Ca^2+^ exchanger 1 (NCX1)                                                                Lencesova *et al*. [2004](#tjp7102-bib-0077){ref-type="ref"}; Mohler *et al*. [2005](#tjp7102-bib-0095){ref-type="ref"}
  Orai‐1 (Ca^2+^ release‐activated Ca^2+^ channel 1)                                             Woodard *et al*. [2010](#tjp7102-bib-0177){ref-type="ref"}; Lur *et al*. [2011](#tjp7102-bib-0082){ref-type="ref"}
  Plasma membrane Ca^2+^ ATPase (PMCA)                                                           Shin *et al*. [2000](#tjp7102-bib-0132){ref-type="ref"}; Huang *et al*. [2006](#tjp7102-bib-0058){ref-type="ref"}
  Protein kinase C (PKC)                                                                         Ferris *et al*. [1991](#tjp7102-bib-0037){ref-type="ref"}; Rex *et al*. [2010](#tjp7102-bib-0122){ref-type="ref"}
  SERCA 2B/3 (sarco/endoplasmic reticulum Ca^2+^‐ATPase)                                         Redondo *et al*. [2008](#tjp7102-bib-0121){ref-type="ref"}
  STIM1 (stromal interaction molecule 1)                                                         Santoso *et al*. [2011](#tjp7102-bib-0124){ref-type="ref"}
  TRPC1‐7 (transient receptor potential canonical channels)                                      Boulay *et al*. [1999](#tjp7102-bib-0017){ref-type="ref"}; Mery *et al*. [2001](#tjp7102-bib-0093){ref-type="ref"}; Tang *et al*. [2001](#tjp7102-bib-0147){ref-type="ref"}; Yuan *et al*. [2003](#tjp7102-bib-0184){ref-type="ref"}; Tong *et al*. [2004](#tjp7102-bib-0155){ref-type="ref"}
  VDAC1 (voltage‐dependent anion channel 1)                                                      Szabadkai *et al*. [2006](#tjp7102-bib-0143){ref-type="ref"}

IRBIT also inhibits IP~3~Rs by occluding the IP~3~‐binding site (Table [2](#tjp7102-tbl-0002){ref-type="table-wrap"}).
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###### 

Other proteins that form complexes with IP~3~Rs

  Protein                                                                          References
  -------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cytoskeletal, scaffolding and adaptor proteins                                   
  14‐3‐3 protein zeta/delta (PKC inhibitor protein 1)                              Angrand *et al*. [2006](#tjp7102-bib-0004){ref-type="ref"}
  α‐Actin                                                                          Sugiyama *et al*. [2000](#tjp7102-bib-0140){ref-type="ref"}
  Ankyrin‐B (ANK2)                                                                 Hayashi & Su, [2001](#tjp7102-bib-0050){ref-type="ref"}; Mohler *et al*. [2004](#tjp7102-bib-0096){ref-type="ref"}; Kline *et al*. [2008](#tjp7102-bib-0070){ref-type="ref"}
  AKAP9 (A‐kinase anchor protein 9; Yotiao)                                        Tu *et al*. [2004](#tjp7102-bib-0159){ref-type="ref"}
  BANK1 (B‐cell scaffold protein with ankyrin repeats)                             Yokoyama *et al*. [2002](#tjp7102-bib-0180){ref-type="ref"}
  Caveolin‐1                                                                       Murata *et al*. [2007](#tjp7102-bib-0100){ref-type="ref"}; Sundivakkam *et al*. [2009](#tjp7102-bib-0141){ref-type="ref"}; Jin *et al*. [2013](#tjp7102-bib-0063){ref-type="ref"}
  Coiled‐coil domain‐containing protein 8                                          Hanson *et al*. [2014](#tjp7102-bib-0048){ref-type="ref"}
  Homer 1/2/3                                                                      Tu *et al*. [1998](#tjp7102-bib-0160){ref-type="ref"}
  EB1 / EB3 (end‐binding protein 1/3)[a](#tjp7102-tbl4-note-0002){ref-type="fn"}   Geyer *et al*. [2015](#tjp7102-bib-0044){ref-type="ref"}
  KRAP (K‐Ras‐induced actin‐interacting protein)                                   Fujimoto *et al*. [2011](#tjp7102-bib-0041){ref-type="ref"}
  LAT (linker of activated T‐cells)                                                deSouza *et al*. [2007](#tjp7102-bib-0034){ref-type="ref"}
  Myosin‐2A                                                                        Walker *et al*. [2002](#tjp7102-bib-0168){ref-type="ref"}; Hours & Mery, [2010](#tjp7102-bib-0057){ref-type="ref"}
  Obscurin‐like protein 1                                                          Hanson *et al*. [2014](#tjp7102-bib-0048){ref-type="ref"}
  Protein 4.1N (band 4.1‐like protein 1)                                           Maximov *et al*. [2003](#tjp7102-bib-0091){ref-type="ref"}
  SEC8 (exocyst complex component)                                                 Shin *et al*. [2000](#tjp7102-bib-0132){ref-type="ref"}
  SNAP‐29 (synaptosomal‐associated protein 29)                                     Huttlin *et al*. [2013](#tjp7102-bib-0060){ref-type="ref"}
  α‐Spectrin/β‐spectrin (α/β‐fodrin)                                               Lencesova *et al*. [2004](#tjp7102-bib-0077){ref-type="ref"}
  Syntaxin 1B                                                                      Tanaka *et al*. [2011](#tjp7102-bib-0146){ref-type="ref"}
  Talin                                                                            Sugiyama *et al*. [2000](#tjp7102-bib-0140){ref-type="ref"}
  Vimentin                                                                         Dingli *et al*. [2012](#tjp7102-bib-0035){ref-type="ref"}
  Vinculin                                                                         Sugiyama *et al*. [2000](#tjp7102-bib-0140){ref-type="ref"}
  Other proteins                                                                   
  Anaplastic lymphoma kinase (ALK)                                                 Crockett *et al*. [2004](#tjp7102-bib-0030){ref-type="ref"}
  ARHGAP1 (Rho GTPase‐activating protein 1)                                        Nagaraja & Kandpal, [2004](#tjp7102-bib-0102){ref-type="ref"}
  γ‐BBH (γ‐butyrobetaine dioxygenase)                                              Huttlin *et al*. [2013](#tjp7102-bib-0060){ref-type="ref"}
  Beclin‐1                                                                         Vicencio *et al*. [2009](#tjp7102-bib-0165){ref-type="ref"}
  BOK (Bcl‐2‐related ovarian killer protein)                                       Schulman *et al*. [2013](#tjp7102-bib-0128){ref-type="ref"}
  Calnexin                                                                         Joseph *et al*. [1999](#tjp7102-bib-0064){ref-type="ref"}
  CD44 antigen (heparin sulphate proteoglycan)                                     Singleton & Bourguignon, [2004](#tjp7102-bib-0135){ref-type="ref"}
  CEMIP (cell migration‐inducing and hyaluronan‐binding protein)                   Tiwari *et al*. [2013](#tjp7102-bib-0154){ref-type="ref"}
  Cyclophilin D (peptidyl‐prolyl cis‐trans isomerase F)                            Paillard *et al*. [2013](#tjp7102-bib-0111){ref-type="ref"}
  FAM19A4 (chemokine‐like protein TAFA‐4)                                          Huttlin *et al*. [2013](#tjp7102-bib-0060){ref-type="ref"}
  F‐box and leucine‐rich repeat protein 14                                         Huttlin *et al*. [2013](#tjp7102-bib-0060){ref-type="ref"}
  FGL2 (fibrinogen‐like 2)                                                         Huttlin *et al*. [2013](#tjp7102-bib-0060){ref-type="ref"}
  FERM domain‐containing 1                                                         Huttlin *et al*. [2013](#tjp7102-bib-0060){ref-type="ref"}
  GluRδ2 (ionotropic glutamate receptor δ2)                                        Nakamura *et al*. [2004](#tjp7102-bib-0103){ref-type="ref"}
  Golgi anti‐apoptotic protein (GAAP; Lifeguard 4; TMBIM4)                         de Mattia *et al*. [2009](#tjp7102-bib-0033){ref-type="ref"}
  GRP‐75 (glucose‐regulated protein 75; stress‐70 protein)                         Szabadkai *et al*. [2006](#tjp7102-bib-0143){ref-type="ref"}
  Heat shock protein 90 (HSP90)                                                    Nguyen *et al*. [2009](#tjp7102-bib-0106){ref-type="ref"}
  Junctate                                                                         Treves *et al*. [2004](#tjp7102-bib-0157){ref-type="ref"}
  Lethal(3)malignant brain tumor‐like protein 2                                    Huttlin *et al*. [2013](#tjp7102-bib-0060){ref-type="ref"}
  Lymphoid‐restricted membrane protein (LRMP; JAW1)                                Shindo *et al*. [2010](#tjp7102-bib-0133){ref-type="ref"}
  Na^+^/K^+^‐transporting ATPase                                                   Mohler *et al*. [2005](#tjp7102-bib-0095){ref-type="ref"}; Yuan *et al*. [2005](#tjp7102-bib-0185){ref-type="ref"}
  Neuronal acetylcholine receptor α3                                               Huttlin *et al*. [2013](#tjp7102-bib-0060){ref-type="ref"}
  PASK (PAS domain‐containing protein kinase)                                      Schlafli *et al*. [2011](#tjp7102-bib-0125){ref-type="ref"}
  Phospholamban                                                                    Koller *et al*. [2003](#tjp7102-bib-0071){ref-type="ref"}
  Polycystin‐2 (PC2; TRPP2)                                                        Li *et al*. [2005](#tjp7102-bib-0080){ref-type="ref"}
  Protein kinase G1 (PKG1; cGMP‐dependent protein kinase 1)                        Schlossman *et al*. [2000](#tjp7102-bib-0127){ref-type="ref"}
  PTPα (protein tyrosine phosphatase‐α)                                            Wang *et al*. [2009](#tjp7102-bib-0169){ref-type="ref"}
  Rab29 (Ras‐related protein Rab7L1)                                               Huttlin *et al*. [2013](#tjp7102-bib-0060){ref-type="ref"}
  Rac1 (Ras‐related C3 botulinum toxin substrate 1; TC25)                          Natsvlishvili *et al*. [2015](#tjp7102-bib-0105){ref-type="ref"}
  RhoA                                                                             Mehta *et al*. [2003](#tjp7102-bib-0092){ref-type="ref"}
  Sigma 1 receptor (σ1R)                                                           Hayashi & Su, [2001](#tjp7102-bib-0050){ref-type="ref"}; Natsvlishvili *et al*. [2015](#tjp7102-bib-0105){ref-type="ref"}
  Sirtuin‐7                                                                        Tsai *et al*. [2012](#tjp7102-bib-0158){ref-type="ref"}
  c‐Src (proto‐oncogene tyrosine‐protein kinase Src)                               Jayaraman *et al*. [1996](#tjp7102-bib-0062){ref-type="ref"}; Wang *et al*. [2009](#tjp7102-bib-0169){ref-type="ref"}
  STARD13 (StAR‐related lipid transfer protein 13; RhoGAP)                         Nagaraja & Kandpal, [2004](#tjp7102-bib-0102){ref-type="ref"}
  Syndecan‐1 (SYND1; CD138)                                                        Maximov *et al*. [2003](#tjp7102-bib-0091){ref-type="ref"}
  TESPA1 (thymocyte‐expressed positive selection‐associated protein 1)             Matsuzaki *et al*. [2012](#tjp7102-bib-0089){ref-type="ref"}

Both EB1 and EB3 associate with IP~3~Rs, but only EB3 has been shown to be required for effective Ca^2+^ signalling in endothelial cells (Table [1](#tjp7102-tbl-0001){ref-type="table-wrap"}) (Geyer *et al*. [2015](#tjp7102-bib-0044){ref-type="ref"}).
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Although we focus on the ability of IP~3~Rs to release Ca^2+^ from intracellular stores, IP~3~Rs have additional roles. For example, binding of IP~3~ is proposed to release IRBIT from the IP~3~‐binding site, freeing IRBIT to regulate additional targets that include ion channels, transporters and the enzyme ribonucleotide reductase (Ando *et al*. [2014](#tjp7102-bib-0002){ref-type="ref"}; Arnaoutov & Dasso, [2014](#tjp7102-bib-0005){ref-type="ref"}). IP~3~Rs may also regulate associated proteins independently of their ability to release Ca^2+^. For example, a direct interaction between IP~3~Rs and TRPC (transient receptor potential canonical) channels is proposed to stimulate opening of the latter (Zhang *et al*. [2001](#tjp7102-bib-0189){ref-type="ref"}). Hence, when reviewing the effects of proteins associated with IP~3~Rs, we should look beyond the effects of IP~3~ on cytosolic Ca^2+^ signals, to consider also consequences within the ER lumen, effects on Ca^2+^ entry, and effects unrelated to Ca^2+^ signalling. That scope is too ambitious for this short review. Instead we provide a comprehensive summary of proteins suggested to interact with IP~3~Rs (Tables [1](#tjp7102-tbl-0001){ref-type="table-wrap"}, [2](#tjp7102-tbl-0002){ref-type="table-wrap"}, [3](#tjp7102-tbl-0003){ref-type="table-wrap"}, [4](#tjp7102-tbl-0004){ref-type="table-wrap"}, within which we provide most references) and then explore a few selected examples to illustrate some general features.

Signalling complexes containing IP~3~Rs span entire signalling pathways {#tjp7102-sec-0030}
=======================================================================

The sheer number of proteins reported to form complexes with IP~3~Rs is striking and so too is their diversity, in terms of both cellular geography and function (Tables [1](#tjp7102-tbl-0001){ref-type="table-wrap"}, [2](#tjp7102-tbl-0002){ref-type="table-wrap"}, [3](#tjp7102-tbl-0003){ref-type="table-wrap"}, [4](#tjp7102-tbl-0004){ref-type="table-wrap"}). IP~3~Rs form complexes with many of the proteins that link extracellular stimuli to formation of IP~3~, including G protein‐coupled receptors (GPCRs), the epidermal growth factor receptor (EGFR), the erythropoietin receptor, the Gβγ complexes of G proteins, and some forms of PLC. IP~3~Rs also associate with other signalling proteins linked to PLC signalling, including protein kinase C (PKC), RACK1 (receptor of activated PKC) and the phosphoinositide phosphatase PTEN. The interactions extend also to proteins from other signalling pathways, including adenylyl cyclase (AC), the small G protein K‐Ras, and the protein kinases AKT1 (RAC‐α serine/threonine protein kinase), mTOR (mammalian target of rapamycin), c‐Src and MAPK1/MAPK3 (mitogen‐activated protein kinase 1/3) (Tables [1](#tjp7102-tbl-0001){ref-type="table-wrap"}, [2](#tjp7102-tbl-0002){ref-type="table-wrap"}, [3](#tjp7102-tbl-0003){ref-type="table-wrap"}, [4](#tjp7102-tbl-0004){ref-type="table-wrap"} and Fig. [1](#tjp7102-fig-0001){ref-type="fig"}). Proteins that respond to the Ca^2+^ released by IP~3~Rs also form complexes with IP~3~Rs. These include ion channels, exchangers and pumps within the plasma membrane. It is clear that IP~3~Rs reside within macromolecular complexes that both span entire signalling pathways from cell‐surface receptors to the effectors that respond to Ca^2+^, and include proteins that integrate signals from other signalling pathways.

The advantages of these signalling complexes are clear. They allow information to be directed selectively from specific extracellular stimuli to specific intracellular targets through conserved signalling pathways. Furthermore, associated proteins can integrate signals from different signalling pathways and so modulate traffic through the complex. Hence, protein complexes confer both specificity and plasticity. A third advantage is speed. Signalling pathways must be able to turn on and off quickly. Fast activation benefits from high concentrations of reactants and fast on‐rates (*k* ~1~) for association of messengers with their targets. Rapid de‐activation requires rapid destruction or dissipation of the messenger and a fast dissociation rate (*k* ~−1~). By facilitating delivery of messengers at high local concentrations to their targets (e.g. IP~3~ to IP~3~Rs), signalling complexes contribute to both rapid activation and de‐activation, the latter because diffusion of messengers away from the site of delivery may be sufficient to allow their concentration to fall below that required for activation as soon as synthesis of the messenger ceases. Secondly, targets can have fast off‐rates (*k* ~−1~) with a corresponding loss of affinity (equilibrium association constant, *K* ~A~ = *k* ~1~/*k* ~−1~) that does not compromise their capacity to respond to high local concentrations of messenger. We suggest, then, that assembly of proteins around IP~3~Rs contributes to fast and specific signalling, while providing opportunities for signal integration and plasticity.

For convenience, we consider the proteins that associate with IP~3~Rs under four somewhat arbitrary (and overlapping) headings: proteins that enhance or inhibit the activity of IP~3~Rs (Tables [1](#tjp7102-tbl-0001){ref-type="table-wrap"} and [2](#tjp7102-tbl-0002){ref-type="table-wrap"}); proteins that respond to Ca^2+^ released by IP~3~Rs (Table [3](#tjp7102-tbl-0003){ref-type="table-wrap"}); and proteins with more general roles, including those associated with movement of IP~3~Rs (Table [4](#tjp7102-tbl-0004){ref-type="table-wrap"}).

Proteins that enhance the function of IP~3~Rs {#tjp7102-sec-0040}
=============================================

Usually, IP~3~Rs open only when they have bound both IP~3~ and Ca^2+^ (Foskett *et al*. [2007](#tjp7102-bib-0038){ref-type="ref"}; Taylor & Tovey, [2010](#tjp7102-bib-0151){ref-type="ref"}). Unsurprisingly, therefore, most of the proteins that associate with IP~3~Rs and enhance their activity do so either by allowing more effective delivery of IP~3~ and/or Ca^2+^ to IP~3~Rs, or by enhancing the responsiveness of IP~3~Rs to IP~3~ and/or Ca^2+^ (Table [1](#tjp7102-tbl-0001){ref-type="table-wrap"}).

The association of IP~3~Rs with GPCRs, EGFR and erythropoietin receptors, with the βγ subunits of G proteins, with some isoforms of PLC, and with scaffold proteins, like Homer 1 that tethers IP~3~Rs to metabotropic glutamate receptors and PLC (Tu *et al*. [1998](#tjp7102-bib-0160){ref-type="ref"}), suggest mechanisms by which receptors may effectively deliver IP~3~ to specific IP~3~Rs. This targeted delivery of IP~3~ provides two advantages: it allows rapid responses and it may allow spatially organized Ca^2+^ signals to retain an 'imprint' of the stimulus that evoked them. Bradykinin B~2~ receptors (B~2~Rs) are a well‐defined example. In sympathetic neurons, both muscarinic M~1~ receptors (M~1~Rs) and B~2~Rs activate PLC, but only activation of B~2~Rs evokes Ca^2+^ release through IP~3~Rs (Delmas *et al*. [2002](#tjp7102-bib-0032){ref-type="ref"}). This selectivity arises because B~2~Rs, but not M~1~Rs, form complexes with IP~3~Rs. Rapid generation of IP~3~ in response to activation of B~2~Rs thereby generates relatively high concentrations of IP~3~ in the vicinity of IP~3~Rs, which are not achieved by the more distant M~1~Rs. In this case, selective coupling between plasma membrane receptors and IP~3~Rs may allow sympathetic neurons to generate different intracellular responses to pro‐inflammatory and cholinergic inputs.

Rather than enhancing the delivery of IP~3~ to IP~3~Rs, many other proteins sensitize IP~3~Rs to prevailing concentrations of IP~3~ and/or Ca^2+^ (Table [1](#tjp7102-tbl-0001){ref-type="table-wrap"}). An example, which may play an important role in human disease, is the sensitization of IP~3~Rs by mutant forms of presenilins (Cheung *et al*. [2008](#tjp7102-bib-0028){ref-type="ref"}). Mutations in presenilin‐1 (PS1) and presenilin‐2 (PS2) are major causes of familial Alzheimer\'s disease. Although both wild‐type and mutant presenilins associate with IP~3~Rs, only the disease‐causing mutant forms of PS1 and PS2 enhance the activity of IP~3~Rs in response to IP~3~ and Ca^2+^. The mechanism involved may be a change in the modal gating of IP~3~Rs (Cheung *et al*. [2010](#tjp7102-bib-0027){ref-type="ref"}). This increased activity of IP~3~Rs results in enhanced release of Ca^2+^, which may lead to aberrant processing of β‐amyloid (Cheung *et al*. [2008](#tjp7102-bib-0028){ref-type="ref"}), constitutive activation of cyclic AMP response element binding protein (CREB)‐mediated transcription (Muller *et al*. [2011](#tjp7102-bib-0099){ref-type="ref"}), synaptic dysfunction and neuronal degeneration (Mattson, [2010](#tjp7102-bib-0090){ref-type="ref"}).

Although activation of IP~3~Rs normally requires binding of IP~3~ and Ca^2+^, a few proteins have been reported to cause reversible activation of IP~3~Rs directly, without the coincident presence of IP~3~ and Ca^2+^ (Table [1](#tjp7102-tbl-0001){ref-type="table-wrap"}). These include Gβγ (Zeng *et al*. [2003](#tjp7102-bib-0187){ref-type="ref"}), CIB1 (White *et al*. [2006](#tjp7102-bib-0175){ref-type="ref"}) and, more controversially, CaBP1 (Yang *et al*. [2002](#tjp7102-bib-0179){ref-type="ref"}). The initial report on the actions of CaBP1 described an activation of *Xenopus* IP~3~Rs in the absence of IP~3~ *in vitro*. However, subsequent studies have demonstrated that CaBP1 inhibits Ca^2+^ release via mammalian and *Xenopus* IP~3~Rs by stabilizing an inactive state of the IP~3~R (Haynes *et al*. [2004](#tjp7102-bib-0051){ref-type="ref"}; Nadif Kasri *et al*. [2004](#tjp7102-bib-0101){ref-type="ref"}; White *et al*. [2006](#tjp7102-bib-0175){ref-type="ref"}; Li *et al*. [2013](#tjp7102-bib-0079){ref-type="ref"}). Similarly, CIB1 was reported to activate IP~3~Rs in *Xenopus* oocytes and Sf9 insect cells in the absence of IP~3~, but it too inhibits Ca^2+^ release via mammalian IP~3~Rs (White *et al*. [2006](#tjp7102-bib-0175){ref-type="ref"}). Uniquely, an irreversible activation of IP~3~Rs appears to occur after proteolytic cleavage by caspase‐3 (Assefa *et al*. [2004](#tjp7102-bib-0006){ref-type="ref"}; Nakayama *et al*. [2004](#tjp7102-bib-0104){ref-type="ref"}), a process that may play a prominent role in apoptosis.

Proteins that inhibit the function of IP~3~Rs {#tjp7102-sec-0050}
=============================================

Many proteins that interact with IP~3~Rs inhibit their function (Table [2](#tjp7102-tbl-0002){ref-type="table-wrap"}). These interactions may enable rapid feedback regulation of Ca^2+^ release and provide long‐term attenuation of IP~3~R activity by promoting degradation or irreversible inhibition of IP~3~Rs. These mechanisms contribute to the tight regulation of IP~3~R activity needed to achieve spatial and temporal organization of Ca^2+^ signals (Konieczny *et al*. [2012](#tjp7102-bib-0073){ref-type="ref"}). They also provide protection from the damaging consequences of excessive increases in cytosolic free Ca^2+^ concentration (Orrenius *et al*. [2015](#tjp7102-bib-0110){ref-type="ref"}) and disturbance of the other essential roles of the ER while it fulfils its role in Ca^2+^ signalling (Berridge, [2002](#tjp7102-bib-0010){ref-type="ref"}). Proteins that inhibit IP~3~Rs in a Ca^2+^‐dependent manner, like calmodulin, CaBP1, calcineurin, CaMKII and the unidentified protein(s) that may mediate the universal inhibition of IP~3~Rs by Ca^2+^, are prime candidates for mediating this negative feedback. Proteins that inhibit IP~3~Rs fall into two broad categories: those that bind reversibly to interfere with binding of IP~3~ and/or Ca^2+^ or their links to gating; and those that cause post‐translational modifications of the IP~3~R (Table [2](#tjp7102-tbl-0002){ref-type="table-wrap"}).

IRBIT inhibits all three IP~3~R subtypes by competing with IP~3~ for binding to the IBC (Ando *et al*. [2003](#tjp7102-bib-0003){ref-type="ref"}). IRBIT binds only when it is phosphorylated at several sites, probably because the phosphorylated residues mimic the essential phosphate groups of IP~3~ (Fig. [2](#tjp7102-fig-0002){ref-type="fig"} *A*). Residue S68 is the 'master' phosphorylation site. When it is phosphorylated by a Ca^2+^‐dependent kinase, perhaps a Ca^2+^/calmodulin‐dependent protein kinase (CaMK), it allows casein kinase I‐mediated phosphorylation of the two residues (S71 and S74, residue numbering relates to mouse IP~3~R1) that are critical for binding of IRBIT to IP~3~Rs (and its other targets) (Ando *et al*. [2014](#tjp7102-bib-0002){ref-type="ref"}). Dephosphorylation of S68 is catalysed by protein phosphatase 1 (PP1), which also associates with IRBIT. The competition between phospho‐IRBIT and IP~3~ for occupancy of the IBC through which IP~3~ initiates activation of IP~3~Rs allows IRBIT to tune the sensitivity of IP~3~Rs to IP~3~. Hence, inhibiting expression of IRBIT, or expression of a dominant negative form (IRBIT‐S68A), allows Ca^2+^ release at lower concentrations of IP~3~ (Ando *et al*. [2014](#tjp7102-bib-0002){ref-type="ref"}). This tuning of IP~3~R sensitivity has been demonstrated in sympathetic neurons where, as discussed earlier, M~1~Rs do not associate with IP~3~Rs and do not normally generate sufficient IP~3~ to activate more distant IP~3~Rs (Delmas *et al*. [2002](#tjp7102-bib-0032){ref-type="ref"}). However, expression of the dominant negative IRBIT allows M~1~Rs to evoke Ca^2+^ release through IP~3~Rs (Zaika *et al*. [2011](#tjp7102-bib-0186){ref-type="ref"}). Although the details are not fully resolved, the interplay between Ca^2+^ and the activation of IRBIT is intriguing because it suggests potential feedback loops that might control the sensitivity of IP~3~Rs to IP~3~ (Ando *et al*. [2014](#tjp7102-bib-0002){ref-type="ref"}). The phosphorylation (of S68) that initiates activation of IRBIT is Ca^2+^ sensitive, deactivation of IRBIT by proteolytic cleavage within its N‐terminal may be mediated by Ca^2+^‐sensitive calpain, and IRBIT itself inhibits Ca^2+^/calmodulin‐dependent protein kinase IIα (CaMKIIα) (Kawaai *et al*. [2015](#tjp7102-bib-0068){ref-type="ref"}) (Fig. [2](#tjp7102-fig-0002){ref-type="fig"} *B*).

![**IRBIT controls the sensitivity of IP~3~Rs**\
*A*, the N‐terminal region of IRBIT includes a serine‐rich domain. Phosphorylation of S68, the 'master' phosphorylation site, allows sequential phosphorylation of the two residues, S71 and S74, that must be phosphorylated for IRBIT to bind to IP~3~Rs. Protein phosphatase 1 (PP1) bound to IRBIT dephosphorylates S68. *B*, phosphorylation of IRBIT (1) allows it to bind to the IBC and so compete with IP~3~ for binding to the IP~3~R. Phospho‐IRBIT thereby sets the sensitivity of the IP~3~R to IP~3~. IP~3~ binding to the IBC (2) prevents IRBIT binding and initiates activation of the IP~3~R. The displaced phospho‐IRBIT can regulate many additional targets, including ion channels and transporters (3). The Ca^2+^ released by active IP~3~Rs may control the phosphorylation state of IRBIT, and thereby complete a feedback loop that regulates IP~3~R sensitivity (4).](TJP-594-2849-g003){#tjp7102-fig-0002}

Post‐translational modification of IP~3~Rs by associated proteins may be reversible (e.g. phosphorylation) (Betzenhauser & Yule, [2010](#tjp7102-bib-0012){ref-type="ref"}) or irreversible (e.g. proteolysis and some covalent modifications). An example of the latter is the Ca^2+^‐dependent enzyme transglutaminase type 2 (TGM2). By covalently modifying a glutamine residue within the C‐terminal tail of IP~3~R1, TGM2 causes irreversible cross‐linking of adjacent IP~3~R subunits via a lysine residue and the modified glutamine. This prevents the conformational changes required for activation of IP~3~Rs, and so inhibits IP~3~‐evoked Ca^2+^ release (Hamada *et al*. [2014](#tjp7102-bib-0047){ref-type="ref"}). The Ca^2+^ sensitivity of TGM2 may allow it to contribute to feedback control of Ca^2+^ release and to disruption of IP~3~R function when dysregulation of Ca^2+^ signalling occurs in pathological conditions such as Huntington\'s disease (Hamada *et al*. [2014](#tjp7102-bib-0047){ref-type="ref"}). Activation of IP~3~Rs and the ensuing release of Ca^2+^ also trigger ubiquitination and proteasomal degradation of IP~3~Rs (Pearce *et al*. [2009](#tjp7102-bib-0116){ref-type="ref"}) and their cleavage by calpains (Μagnusson *et al*. [1993](#tjp7102-bib-0084){ref-type="ref"}; Wojcikiewicz & Oberdorf, [1996](#tjp7102-bib-0176){ref-type="ref"}). Hence, proteins that associate with IP~3~Rs provide mechanisms that allow both acute and long‐term feedback regulation of IP~3~R activity.

Downstream effectors {#tjp7102-sec-0060}
====================

IP~3~Rs also form complexes with proteins that are downstream effectors of IP~3~R activation; most of these respond to the Ca^2+^ released by IP~3~Rs (Table [3](#tjp7102-tbl-0003){ref-type="table-wrap"}). Many of these proteins are cytosolic, but others reside within membranes that allow IP~3~Rs within the ER to communicate with other intracellular organelles or the plasma membrane. The importance of this communication between organelles, mediated by junctional complexes between them, is increasingly recognized (Lam & Galione, [2013](#tjp7102-bib-0076){ref-type="ref"}).

Hepatic gluconeogenesis, which is likely to play an important role in diabetes and obesity, is stimulated by glucagon released by the pancreas during fasting, and inhibited by insulin released when the plasma glucose concentration increases. A complex containing IP~3~Rs, the Ca^2+^‐regulated protein phosphatase calcineurin, the transcriptional co‐activator of CREB‐regulated transcription CRTC2 (CREB‐coactivator C2), PKA and AKT1 coordinates gluconeogenesis (Wang *et al*. [2012](#tjp7102-bib-0170){ref-type="ref"}) (Fig. [3](#tjp7102-fig-0003){ref-type="fig"}). De‐phosphorylated CRTC2 binds to nuclear CREB and up‐regulates genes that promote gluconeogenesis. This is repressed by SIK2, a kinase that phosphorylates CRTC2. IP~3~‐evoked Ca^2+^ release activates calcineurin, which de‐phosphorylates CRTC2. Glucagon receptors stimulate production of both cAMP and IP~3~ (Wakelam *et al*. [1986](#tjp7102-bib-0167){ref-type="ref"}; Wang *et al*. [2012](#tjp7102-bib-0170){ref-type="ref"}). The cAMP activates PKA, which phosphorylates, and thereby inhibits, SIK2; and it phosphorylates IP~3~Rs, sensitizing them to activation by IP~3~ and Ca^2+^. IP~3~Rs are also directly sensitized by cAMP (Tovey *et al*. [2008](#tjp7102-bib-0156){ref-type="ref"}). Increased release of Ca^2+^ via IP~3~Rs activates calcineurin, which dephosphorylates CRTC2 (Vanderheyden *et al*. [2009](#tjp7102-bib-0162){ref-type="ref"} *a*; Wang *et al*. [2012](#tjp7102-bib-0170){ref-type="ref"}). Hence glucagon both inhibits the kinase (SIK2) and stimulates the phosphatase (calcineurin) that control phosphorylation of CRTC2. Glucagon also reduces binding of CRTC2 to IP~3~Rs (Wang *et al*. [2012](#tjp7102-bib-0170){ref-type="ref"}), further enhancing the nuclear translocation of dephosphorylated CRTC2. The signals evoked by insulin receptors also feed into this IP~3~R complex. Insulin stimulates phosphatidylinositol 3‐kinase (PI3K) and thereby AKT1. The latter phosphorylates IP~3~Rs and attenuates their activity. Hence insulin, by inhibiting IP~3~Rs, opposes the actions of glucagon by restraining the activation of calcineurin and so maintains CRTC2 in its inactive phosphorylated state (Wang *et al*. [2012](#tjp7102-bib-0170){ref-type="ref"}). This example illustrates some of the intricate interactions that the assembly of proteins around IP~3~Rs can allow: signals from a GPCR and a receptor tyrosine kinase converge at IP~3~Rs, which then integrate the inputs and transduce them into a regulation of gene expression (Fig. [3](#tjp7102-fig-0003){ref-type="fig"}).

![**A signalling complex assembled around IP~3~Rs controls gluconeogenesis**\
Glucagon and insulin exert opposing effects on hepatic gluconeogenesis. Their signalling pathways converge to a protein complex assembled around IP~3~Rs, the activity of which controls phosphorylation of the transcription factor CRTC2. Dephosphorylated CRTC2 translocates to the nucleus, where it associates with CREB and stimulates transcription of genes required for gluconeogenesis. SIK2 phosphorylates CRTC2, while calcineurin dephosphorylates it. Glucagon, via a GPCR, stimulates both PLC and AC. The IP~3~ produced by PLC stimulates IP~3~Rs. The cAMP generated by AC stimulates PKA and that promotes dephosphorylation of CRTC2 by phosphorylating both SIK2 (inhibiting its activity) and IP~3~Rs, sensitizing the latter to IP~3~. The larger Ca^2+^ signal then activates calcineurin. Insulin causes activation of AKT1, which phosphorylates IP~3~Rs and inhibits their activity; it thereby opposes the effects of glucagon and attenuates calcineurin activity. Phosphorylation is indicated by red circles, black arrows denote stimulation and the red arrow denotes inhibition. Abbreviations and further details in the text and tables.](TJP-594-2849-g004){#tjp7102-fig-0003}

Proteins that determine the distribution of IP~3~Rs {#tjp7102-sec-0070}
===================================================

The subcellular distribution of IP~3~Rs is an important influence on their behaviour, not least because it defines the sites at which they will release Ca^2+^, and whether they will be exposed to effective concentrations of the stimuli that activate them, IP~3~ and Ca^2+^. Assembly of IP~3~Rs with components of the PLC signalling pathway (see above) can ensure targeted delivery of IP~3~, but Ca^2+^ is most often provided by neighbouring IP~3~Rs. An important interaction, therefore, is that between IP~3~Rs themselves, because their proximity to neighbours dictates whether Ca^2+^ released by an active IP~3~R can ignite the activity of other IP~3~Rs. Considerable evidence suggests that clustering of IP~3~Rs within the plane of the ER membrane is dynamically regulated by IP~3~ and/or Ca^2+^ (Tateishi *et al*. [2005](#tjp7102-bib-0150){ref-type="ref"}; Rahman *et al*. [2009](#tjp7102-bib-0120){ref-type="ref"}; and see references in Geyer *et al*. [2015](#tjp7102-bib-0044){ref-type="ref"}), although the role of this process in shaping Ca^2+^ signals remains controversial (Smith *et al*. [2014](#tjp7102-bib-0137){ref-type="ref"}). We have suggested that IP~3~‐evoked clustering of IP~3~Rs may contribute to the coordinated openings of IP~3~Rs that underlie the small Ca^2+^ signals ('Ca^2+^ puffs') evoked by low stimulus intensities, by both bringing IP~3~Rs together and retuning their Ca^2+^ sensitivity (Rahman *et al*. [2009](#tjp7102-bib-0120){ref-type="ref"}). Head‐to‐head interactions of IP~3~Rs have also been observed in electron micrographs of purified IP~3~Rs (Hamada *et al*. [2003](#tjp7102-bib-0046){ref-type="ref"}), between opposing ER membranes within cells (Takei *et al*. [1994](#tjp7102-bib-0145){ref-type="ref"}) and between the isolated N‐terminal domains of IP~3~Rs (Chavda *et al*. [2013](#tjp7102-bib-0025){ref-type="ref"}). The functional significance of these interactions has not been established.

A recent study of the Ca^2+^ signals evoked by thrombin‐mediated stimulation of the protease‐activated receptor PAR‐1 in endothelial cells provides evidence that microtubules may guide IP~3~Rs into the clusters within which Ca^2+^ release can most effectively recruit neighbouring IP~3~Rs (Geyer *et al*. [2015](#tjp7102-bib-0044){ref-type="ref"}). In lung microvascular endothelial cells, thrombin, which activates PAR‐1 by cleaving its N‐terminal, stimulates PLC and thereby evokes Ca^2+^ release through IP~3~Rs. The resulting increase in cytosolic Ca^2+^ concentration contributes to disassembly of the adherens junctions that maintain the integrity of the endothelium (Komarova & Malik, [2010](#tjp7102-bib-0072){ref-type="ref"}). These effects are attenuated when the interaction between type 3 IP~3~Rs (IP~3~R3) and end‐binding protein 3 (EB3) are disrupted. EB3 belongs to a family of proteins that bind to the plus‐end of growing microtubules and recruit other proteins, often via an S/TxIP motif (where x denotes any residue) (Honnappa *et al*. [2009](#tjp7102-bib-0056){ref-type="ref"}). Mutation of the TxIP motif within the regulatory domain of IP~3~R3 prevents its binding to EB3, attenuates thrombin‐evoked Ca^2+^ signals, and reduces both the basal clustering of IP~3~R3 and the enhanced clustering evoked by thrombin. Hence, in endothelial cells, the association of IP~3~R3 with EB3 and microtubules is required for both clustering of IP~3~Rs and effective Ca^2+^ signalling. This suggests that clustering allows IP~3~Rs to deliver Ca^2+^ more effectively to other IP~3~Rs and so allows the amplification provided by Ca^2+^‐induced Ca^2+^ release (Fig. [4](#tjp7102-fig-0004){ref-type="fig"}). We conclude that association of IP~3~Rs with other proteins, components of the PLC signalling pathway or EB3, contributes to effective delivery of the two essential regulators of IP~3~Rs, IP~3~ and Ca^2+^, respectively.

![**EB3 is required for effective signalling by IP~3~Rs in endothelial cells**\
In endothelial cells, EB3 binds to a TxIP motif within the regulatory domain of IP~3~R3, allowing IP~3~Rs to associate with the plus‐end of microtubules. Disrupting this interaction prevents clustering of IP~3~Rs and attenuates the Ca^2+^ signals evoked by thrombin, which cleaves within the N‐terminus of PAR‐1 and allows it to stimulate PLC. The evidence (Geyer *et al*. [2015](#tjp7102-bib-0044){ref-type="ref"}) suggests that the EB3‐mediated interaction of IP~3~R3 with microtubules is essential for the clustering of IP~3~Rs that allows the Ca^2+^ released by one IP~3~R to be amplified by recruitment of neighbouring IP~3~Rs.](TJP-594-2849-g005){#tjp7102-fig-0004}

Conclusions {#tjp7102-sec-0080}
===========

IP~3~Rs and the Ca^2+^ they release are called upon to specifically regulate many physiological processes (Berridge, [2009](#tjp7102-bib-0011){ref-type="ref"}), while neither perturbing the other essential roles of the ER (Berridge, [2002](#tjp7102-bib-0010){ref-type="ref"}) nor subjecting the cell to the deleterious consequences of excessive increases in cytosolic Ca^2+^ concentration (Orrenius *et al*. [2015](#tjp7102-bib-0110){ref-type="ref"}). These demands impose a need for complex regulation of IP~3~Rs, much of which is achieved by assembling proteins around IP~3~Rs to form signalling complexes (Konieczny *et al*. [2012](#tjp7102-bib-0073){ref-type="ref"}). These complexes allow signals to be directed through conserved signalling pathways and endow the pathways with speed, integrative capacity and plasticity. The very large size of IP~3~Rs relative to most other ion channels might be viewed as an evolutionary adaptation to meet this need for them to function as signalling hubs.

Advances in genomics, proteomics, antibody technologies and bioinformatics have transformed analyses of protein--protein interactions. It is now possible to interrogate these interactions on a whole‐proteome scale (Havugimana *et al*. [2012](#tjp7102-bib-0049){ref-type="ref"}; Rolland *et al*. [2014](#tjp7102-bib-0123){ref-type="ref"}). Bioinformatic methods can predict protein--protein interactions (Baughman *et al*. [2011](#tjp7102-bib-0009){ref-type="ref"}; Kotlyar *et al*. [2015](#tjp7102-bib-0074){ref-type="ref"}) and even the regions of the proteins that are involved (Gavenonis *et al*. [2014](#tjp7102-bib-0043){ref-type="ref"}). These powerful technologies, and the opportunities they provide to design new therapies (Wells & McClendon, [2007](#tjp7102-bib-0172){ref-type="ref"}), cannot displace the need for direct confirmation of the interactions and their functional significance. Together, these approaches pave the way to defining the properties and functional importance of IP~3~R signalling hubs in normal physiology and disease.
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